Trial Outcomes & Findings for Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy. (NCT NCT01250184)
NCT ID: NCT01250184
Last Updated: 2014-10-10
Results Overview
VAS with a score of 0-100, where 100 is the value representing the highest degree of pain and 0 the lowest. Successful treatment was defined as a reduction in pain of at least 20% of the previous score on the VAS after 4 weeks of the initial evaluation, or 14 mm on the VAS; this scale is a reliable pain assessment measure that has been validated previously
COMPLETED
PHASE4
127 participants
4 weeks
2014-10-10
Participant Flow
In the databases of two general and specialized medical institutions, 762 patients were identified to have non-specific myalgia or muscle disorders diagnoses. A nurse by phone and two medical physiatrists at the hospitals, with over 10 years of research experience evaluated the MPS patients and their medical history.
The randomization process was performed using permuted blocks.This process was performed by an investigator (HIG) who had no contact with the patients. The allocations to each treatment were placed in consecutive sealed, opaque envelopes, were kept in the research headquarters and were taken to the site according to the number of patients referred.
Participant milestones
| Measure |
Physical Therapy
Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)
|
Lidocaine Injection + Physical Therapy
Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
|
Lidocaine Injection
Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
|
|---|---|---|---|
|
Overall Study
STARTED
|
43
|
41
|
43
|
|
Overall Study
COMPLETED
|
43
|
41
|
43
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy.
Baseline characteristics by cohort
| Measure |
Blocking the MTP Plus Physical Therapy
n=41 Participants
Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
|
Physical Therapy
n=43 Participants
Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)
|
Blocking the MTP
n=43 Participants
Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
|
Total
n=127 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
37.2 years
STANDARD_DEVIATION 11.1 • n=5 Participants
|
42.6 years
STANDARD_DEVIATION 9.7 • n=7 Participants
|
37.7 years
STANDARD_DEVIATION 11.8 • n=5 Participants
|
39.19 years
STANDARD_DEVIATION 11.12 • n=4 Participants
|
|
Sex: Female, Male
Female
|
35 Participants
n=5 Participants
|
36 Participants
n=7 Participants
|
33 Participants
n=5 Participants
|
104 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
6 Participants
n=5 Participants
|
7 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
23 Participants
n=4 Participants
|
|
Region of Enrollment
Colombia
|
41 participants
n=5 Participants
|
43 participants
n=7 Participants
|
43 participants
n=5 Participants
|
127 participants
n=4 Participants
|
|
Concomitant factors
Stress
|
34 participants
n=5 Participants
|
29 participants
n=7 Participants
|
30 participants
n=5 Participants
|
93 participants
n=4 Participants
|
|
Concomitant factors
Sleeplessness
|
24 participants
n=5 Participants
|
18 participants
n=7 Participants
|
23 participants
n=5 Participants
|
65 participants
n=4 Participants
|
|
Concomitant factors
Longer positions
|
27 participants
n=5 Participants
|
34 participants
n=7 Participants
|
29 participants
n=5 Participants
|
90 participants
n=4 Participants
|
|
Muscles with trigger point
Trapezius muscle
|
37 participants
n=5 Participants
|
42 participants
n=7 Participants
|
39 participants
n=5 Participants
|
118 participants
n=4 Participants
|
|
Muscles with trigger point
Levator scapulae
|
31 participants
n=5 Participants
|
27 participants
n=7 Participants
|
26 participants
n=5 Participants
|
84 participants
n=4 Participants
|
|
Muscles with trigger point
Infraspinatus muscle
|
12 participants
n=5 Participants
|
12 participants
n=7 Participants
|
13 participants
n=5 Participants
|
37 participants
n=4 Participants
|
|
Physical examination
Sensitive Alteration
|
8 participants
n=5 Participants
|
7 participants
n=7 Participants
|
8 participants
n=5 Participants
|
23 participants
n=4 Participants
|
|
Physical examination
Referred pain
|
22 participants
n=5 Participants
|
36 participants
n=7 Participants
|
23 participants
n=5 Participants
|
81 participants
n=4 Participants
|
|
Physical examination
Local twitch response
|
29 participants
n=5 Participants
|
26 participants
n=7 Participants
|
22 participants
n=5 Participants
|
77 participants
n=4 Participants
|
|
Visual Analogue Scale for Pain
|
63.5 units on a scale
STANDARD_DEVIATION 13.9 • n=5 Participants
|
68.7 units on a scale
STANDARD_DEVIATION 17 • n=7 Participants
|
64.2 units on a scale
STANDARD_DEVIATION 16.2 • n=5 Participants
|
65.54 units on a scale
STANDARD_DEVIATION 15.9 • n=4 Participants
|
|
Patient Health Questionnaire - 9
|
5.6 units on a scale
STANDARD_DEVIATION 3.2 • n=5 Participants
|
5.9 units on a scale
STANDARD_DEVIATION 4.2 • n=7 Participants
|
5.6 units on a scale
STANDARD_DEVIATION 3.5 • n=5 Participants
|
5.72 units on a scale
STANDARD_DEVIATION 3.68 • n=4 Participants
|
|
Patient Health Questionnaire - 9 How often
Not at all
|
30 participants
n=5 Participants
|
30 participants
n=7 Participants
|
29 participants
n=5 Participants
|
89 participants
n=4 Participants
|
|
Patient Health Questionnaire - 9 How often
Several days
|
9 participants
n=5 Participants
|
8 participants
n=7 Participants
|
14 participants
n=5 Participants
|
31 participants
n=4 Participants
|
|
Patient Health Questionnaire - 9 How often
More than half the days
|
2 participants
n=5 Participants
|
4 participants
n=7 Participants
|
0 participants
n=5 Participants
|
6 participants
n=4 Participants
|
|
Patient Health Questionnaire - 9 How often
Nearly every day
|
0 participants
n=5 Participants
|
1 participants
n=7 Participants
|
0 participants
n=5 Participants
|
1 participants
n=4 Participants
|
|
Quality of Life SF-36
Body pain
|
38.8 units on a scale
STANDARD_DEVIATION 14.4 • n=5 Participants
|
35.2 units on a scale
STANDARD_DEVIATION 14.3 • n=7 Participants
|
38.5 units on a scale
STANDARD_DEVIATION 16.4 • n=5 Participants
|
37.52 units on a scale
STANDARD_DEVIATION 15.2 • n=4 Participants
|
|
Quality of Life SF-36
Role-emotional
|
66.4 units on a scale
STANDARD_DEVIATION 35.0 • n=5 Participants
|
75.8 units on a scale
STANDARD_DEVIATION 38.7 • n=7 Participants
|
67.2 units on a scale
STANDARD_DEVIATION 36.8 • n=5 Participants
|
69.92 units on a scale
STANDARD_DEVIATION 36.89 • n=4 Participants
|
|
Quality of Life SF-36
Role-physical
|
51.2 units on a scale
STANDARD_DEVIATION 40 • n=5 Participants
|
51.1 units on a scale
STANDARD_DEVIATION 37.7 • n=7 Participants
|
42.4 units on a scale
STANDARD_DEVIATION 37.6 • n=5 Participants
|
48.21 units on a scale
STANDARD_DEVIATION 48.36 • n=4 Participants
|
|
Quality of Life SF-36
Physical functioning
|
79.5 units on a scale
STANDARD_DEVIATION 17.8 • n=5 Participants
|
72.5 units on a scale
STANDARD_DEVIATION 20.5 • n=7 Participants
|
81.7 units on a scale
STANDARD_DEVIATION 11.9 • n=5 Participants
|
77.91 units on a scale
STANDARD_DEVIATION 17.5 • n=4 Participants
|
|
Quality of Life SF-36
Social Function
|
69.5 units on a scale
STANDARD_DEVIATION 22 • n=5 Participants
|
68 units on a scale
STANDARD_DEVIATION 26.6 • n=7 Participants
|
71.8 units on a scale
STANDARD_DEVIATION 23.6 • n=5 Participants
|
69.83 units on a scale
STANDARD_DEVIATION 24.06 • n=4 Participants
|
|
Quality of Life SF-36
General health
|
67.4 units on a scale
STANDARD_DEVIATION 18.3 • n=5 Participants
|
57.3 units on a scale
STANDARD_DEVIATION 21.9 • n=7 Participants
|
70.7 units on a scale
STANDARD_DEVIATION 15.4 • n=5 Participants
|
65.12 units on a scale
STANDARD_DEVIATION 19.47 • n=4 Participants
|
|
Quality of Life SF-36
Mental health
|
67.8 units on a scale
STANDARD_DEVIATION 14.2 • n=5 Participants
|
65.5 units on a scale
STANDARD_DEVIATION 18.9 • n=7 Participants
|
67.4 units on a scale
STANDARD_DEVIATION 17.5 • n=5 Participants
|
66.93 units on a scale
STANDARD_DEVIATION 16.95 • n=4 Participants
|
|
Quality of Life SF-36
Vitality
|
54.2 units on a scale
STANDARD_DEVIATION 13.9 • n=5 Participants
|
54.7 units on a scale
STANDARD_DEVIATION 19.2 • n=7 Participants
|
60.7 units on a scale
STANDARD_DEVIATION 19.3 • n=5 Participants
|
56.61 units on a scale
STANDARD_DEVIATION 17.85 • n=4 Participants
|
PRIMARY outcome
Timeframe: 4 weeksPopulation: Was calculated with the software "Sample Size from Javeriana University", was taken into account an error type I of 0.05 and error type II of 0.2, number of measurements before randomization = 1, after performing scrambling = 2, correlation between measurements of 0.6, clinically important difference of 0.35, for a total number of = 45 each
VAS with a score of 0-100, where 100 is the value representing the highest degree of pain and 0 the lowest. Successful treatment was defined as a reduction in pain of at least 20% of the previous score on the VAS after 4 weeks of the initial evaluation, or 14 mm on the VAS; this scale is a reliable pain assessment measure that has been validated previously
Outcome measures
| Measure |
Lidocaine Injection + Physical Therapy
n=41 Participants
Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
|
Lidocaine Injection
n=43 Participants
Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
|
Physical Therapy
n=43 Participants
Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)
|
|---|---|---|---|
|
Visual Analogue Scale
|
40.8 units on a scale
Standard Deviation 25.3
|
44.2 units on a scale
Standard Deviation 24.9
|
37.8 units on a scale
Standard Deviation 21.9
|
PRIMARY outcome
Timeframe: 12 weeksPopulation: Was calculated with the software "Sample Size from Javeriana University", was taken into account an error type I of 0.05 and error type II of 0.2, number of measurements before randomization = 1, after performing scrambling = 2, correlation between measurements of 0.6, clinically important difference of 0.35, for a total number of = 45 each
VAS with a score of 0-100, where 100 is the value representing the highest degree of pain and 0 the lowest. Successful treatment was defined as a reduction in pain of at least 20% of the previous score on the VAS after 4 weeks of the initial evaluation, or 14 mm on the VAS; this scale is a reliable pain assessment measure that has been validated previously
Outcome measures
| Measure |
Lidocaine Injection + Physical Therapy
n=41 Participants
Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
|
Lidocaine Injection
n=43 Participants
Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
|
Physical Therapy
n=43 Participants
Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)
|
|---|---|---|---|
|
Visual Analogue Scale
|
21.6 units on a scale
Standard Deviation 21.8
|
28.8 units on a scale
Standard Deviation 22.3
|
28.2 units on a scale
Standard Deviation 23.7
|
SECONDARY outcome
Timeframe: 4 weeksThe PHQ-9 was developed from the Primary Care Evaluation of Mental Disorders. The self-report instrument asks individuals how much they had been bothered by any of the nine problems over the prior two weeks. Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents the severity of depressive symptoms. 0 - 4 None-minimal None, 5 - 9 Mild, 10 - 14 Moderate, 15 - 19 Moderately Severe, 20 - 27 Severe
Outcome measures
| Measure |
Lidocaine Injection + Physical Therapy
n=41 Participants
Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
|
Lidocaine Injection
n=43 Participants
Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
|
Physical Therapy
n=43 Participants
Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)
|
|---|---|---|---|
|
PHQ 9 Function Measured With the Hand Back and Hand Mouth Maneuvers. Complications and Adverse Reactions Need for Rescue Medication
|
4.33 units on a scale
Standard Deviation 3.647
|
4.44 units on a scale
Standard Deviation 3.03
|
4.43 units on a scale
Standard Deviation 4.073
|
SECONDARY outcome
Timeframe: 4 weeksThe SF-36 consists of 36 items addressing the patient's perception of their quality of life (QoL) in the following eight domains: physical function (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH), and one item change in health. Sub-scale scores range from 0 to 100, with 100 as the best, most positive QoL in that area and 0 is the worst. There is a total scale score, all subscales range from 0 to 100. This scale was validated in Colombia.
Outcome measures
| Measure |
Lidocaine Injection + Physical Therapy
n=41 Participants
Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
|
Lidocaine Injection
n=43 Participants
Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
|
Physical Therapy
n=43 Participants
Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)
|
|---|---|---|---|
|
Quality of Life SF-36
Changing Health
|
70.0 units on a scale
Standard Deviation 18.1
|
67.8 units on a scale
Standard Deviation 16.05
|
60.93 units on a scale
Standard Deviation 18.5
|
|
Quality of Life SF-36
Body pain
|
55.3 units on a scale
Standard Deviation 18.4
|
51.78 units on a scale
Standard Deviation 15.70
|
57.12 units on a scale
Standard Deviation 20.7
|
|
Quality of Life SF-36
Emotional performance
|
78.2 units on a scale
Standard Deviation 35.1
|
78.76 units on a scale
Standard Deviation 33.24
|
85.85 units on a scale
Standard Deviation 27.58
|
|
Quality of Life SF-36
Physical performance
|
73.1 units on a scale
Standard Deviation 40.5
|
74.39 units on a scale
Standard Deviation 33.3
|
73.84 units on a scale
Standard Deviation 34.48
|
|
Quality of Life SF-36
Physical Function
|
86.8 units on a scale
Standard Deviation 13.2
|
86.83 units on a scale
Standard Deviation 11.55
|
82.79 units on a scale
Standard Deviation 15.52
|
|
Quality of Life SF-36
Social Function
|
79.2 units on a scale
Standard Deviation 20.7
|
78.15 units on a scale
Standard Deviation 20.44
|
81.51 units on a scale
Standard Deviation 22.83
|
|
Quality of Life SF-36
General Health
|
72.1 units on a scale
Standard Deviation 16.7
|
73.54 units on a scale
Standard Deviation 13.43
|
65.70 units on a scale
Standard Deviation 20.16
|
|
Quality of Life SF-36
Mental Health
|
73.2 units on a scale
Standard Deviation 16.6
|
69.95 units on a scale
Standard Deviation 17.57
|
70.05 units on a scale
Standard Deviation 19.82
|
|
Quality of Life SF-36
Vitality
|
61.3 units on a scale
Standard Deviation 16
|
62.56 units on a scale
Standard Deviation 17.32
|
59.88 units on a scale
Standard Deviation 19.83
|
SECONDARY outcome
Timeframe: 12 weeksThe PHQ-9 was developed from the Primary Care Evaluation of Mental Disorders. The self-report instrument asks individuals how much they had been bothered by any of the nine problems over the prior two weeks. Items are scored from 0 (not at all) to 3 (nearly every day). Items are summed and the total score (from 0 to 27) represents the severity of depressive symptoms. 0 - 4 None-minimal None, 5 - 9 Mild, 10 - 14 Moderate, 15 - 19 Moderately Severe, 20 - 27 Severe
Outcome measures
| Measure |
Lidocaine Injection + Physical Therapy
n=41 Participants
Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
|
Lidocaine Injection
n=43 Participants
Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
|
Physical Therapy
n=43 Participants
Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)
|
|---|---|---|---|
|
PHQ 9 Function Measured With the Hand Back and Hand Mouth Maneuvers. Complications and Adverse Reactions Need for Rescue Medication
|
3.98 units on a scale
Standard Deviation 3.97
|
3.16 units on a scale
Standard Deviation 2.81
|
4.12 units on a scale
Standard Deviation 4.48
|
SECONDARY outcome
Timeframe: 12 weeksThe SF-36 consists of 36 items addressing the patient's perception of their quality of life (QoL) in the following eight domains: physical function (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH), and one item change in health. Sub-scale scores range from 0 to 100, with 100 as the best, most positive QoL in that area and 0 is the worst. There is a total scale score, all subscales range from 0 to 100. This scale was validated in Colombia.
Outcome measures
| Measure |
Lidocaine Injection + Physical Therapy
n=41 Participants
Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
|
Lidocaine Injection
n=43 Participants
Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
|
Physical Therapy
n=43 Participants
Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)
|
|---|---|---|---|
|
Quality of Life SF-36
Changing Health
|
70.5 units on a scale
Standard Deviation 18.67
|
70.23 units on a scale
Standard Deviation 17.11
|
69.76 units on a scale
Standard Deviation 18.5
|
|
Quality of Life SF-36
Body pain
|
66.58 units on a scale
Standard Deviation 20.09
|
61.19 units on a scale
Standard Deviation 17.67
|
65.66 units on a scale
Standard Deviation 20.9
|
|
Quality of Life SF-36
Emotional performance
|
83.25 units on a scale
Standard Deviation 32.11
|
90.60 units on a scale
Standard Deviation 21.15
|
84.13 units on a scale
Standard Deviation 32.95
|
|
Quality of Life SF-36
Physical performance
|
81.88 units on a scale
Standard Deviation 30.48
|
87.79 units on a scale
Standard Deviation 22.07
|
82.5 units on a scale
Standard Deviation 31.11
|
|
Quality of Life SF-36
Physical Function
|
87.75 units on a scale
Standard Deviation 16.94
|
90 units on a scale
Standard Deviation 9.06
|
89.13 units on a scale
Standard Deviation 12.29
|
|
Quality of Life SF-36
Social Function
|
82.6 units on a scale
Standard Deviation 20.99
|
83.28 units on a scale
Standard Deviation 17.44
|
83.05 units on a scale
Standard Deviation 20.71
|
|
Quality of Life SF-36
General Health
|
71.67 units on a scale
Standard Deviation 17.26
|
77.44 units on a scale
Standard Deviation 12.50
|
68.25 units on a scale
Standard Deviation 22.37
|
|
Quality of Life SF-36
Mental Health
|
75.3 units on a scale
Standard Deviation 16.79
|
78.95 units on a scale
Standard Deviation 14.03
|
71.32 units on a scale
Standard Deviation 17.86
|
|
Quality of Life SF-36
Vitality
|
63.38 units on a scale
Standard Deviation 16.11
|
69.64 units on a scale
Standard Deviation 16.17
|
61.95 units on a scale
Standard Deviation 18.53
|
Adverse Events
Lidocaine Injection + Physical Therapy
Physical Therapy
Lidocaine Injection
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Lidocaine Injection + Physical Therapy
n=41 participants at risk
Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
blocking the MTP plus physical therapy: blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
|
Physical Therapy
n=43 participants at risk
Twelve sessions, 3 per week.
Physical therapy: Twelve sessions (3 per week)
|
Lidocaine Injection
n=43 participants at risk
Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
Blocking the MTP: blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
|
|---|---|---|---|
|
Skin and subcutaneous tissue disorders
Hematomas
|
9.8%
4/41 • Number of events 4 • 1 month
|
0.00%
0/43 • 1 month
|
4.7%
2/43 • Number of events 2 • 1 month
|
|
Skin and subcutaneous tissue disorders
Bleeding
|
0.00%
0/41 • 1 month
|
0.00%
0/43 • 1 month
|
2.3%
1/43 • Number of events 1 • 1 month
|
Additional Information
Dr. Luz Helena Lugo, Head of Research Group Rehabilitation in Health
university of Antioquia, Research Group Rehabilitation in Health
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place